| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Onjisaponin Z targets multiple pathways involved in neuroprotection and inflammation. It modulates oxidative stress responses and inflammatory signaling cascades. The compound's neuroprotective effects suggest interactions with neuronal survival pathways, while its anti-inflammatory activity involves modulation of cytokine production and immune cell function.
|
|---|---|
| ln Vitro |
In vitro, Onjisaponin Z exhibits neuroprotective effects in neuronal cell models by reducing oxidative stress and inflammation. It shows anti-inflammatory activity by modulating the production of proinflammatory cytokines and inhibiting inflammatory signaling pathways. The compound also demonstrates antioxidant properties through scavenging of reactive oxygen species.
|
| ln Vivo |
In vivo, Onjisaponin Z has been evaluated in animal models of neurological disorders and inflammation. As a natural product from Polygala tenuifolia, it contributes to the traditional medicinal uses of this herb for cognitive enhancement and neuroprotection. The compound's anti-inflammatory and antioxidant activities suggest potential benefits in models of neurodegeneration and inflammatory diseases.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Onjisaponin Z typically involve screening against panels of inflammatory and neuroprotective targets. Binding studies are performed using radioligand binding or surface plasmon resonance to assess affinity for specific receptors or enzymes involved in inflammation, oxidative stress, and neuronal survival.
|
| Cell Assay |
Cellular assays for Onjisaponin Z are conducted using neuronal cell lines (e.g., SH-SY5Y, PC12) or immune cells. Cells are treated with the compound at concentrations ranging from 1-100 uM for 6-24 hours. Neuroprotection is assessed in models of oxidative stress (e.g., H2O2 or glutamate toxicity) by measuring cell viability (MTT assay). Anti-inflammatory activity is evaluated by measuring cytokine production (ELISA) and NF-kappaB activation (Western blot).
|
| Animal Protocol |
In vivo studies for Onjisaponin Z are conducted in rodent models of neurodegeneration (e.g., scopolamine-induced cognitive impairment, MPTP-induced Parkinson's model) or inflammation (e.g., carrageenin-induced paw edema). The compound is administered via oral gavage or intraperitoneal injection at doses of 10-100 mg/kg. Cognitive function is assessed by Morris water maze or passive avoidance tests. Inflammatory markers and oxidative stress parameters are measured in brain or peripheral tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Onjisaponin Z are limited. As a triterpenoid saponin, its oral bioavailability is expected to be low due to poor intestinal absorption and extensive metabolism. The compound is typically formulated with appropriate solvents for in vivo administration. Standard storage conditions are powder at -20degC for long-term stability.
|
| Toxicity/Toxicokinetics |
Toxicological information for Onjisaponin Z is not extensively characterized. As a natural product from a medicinal herb, it is generally considered to have a moderate safety profile in research settings. No significant acute toxicity has been reported at the doses used for pharmacological studies. Standard laboratory safety precautions apply when handling the compound.
|
| Additional Infomation |
Onjisaponin Z is a research-use natural product not approved for clinical therapeutic applications. It serves as a valuable tool for studying the neuroprotective, anti-inflammatory, and antioxidant properties of triterpenoid saponins. The compound is used to investigate the traditional medicinal uses of Polygala tenuifolia and to identify potential therapeutic agents for neurodegenerative and inflammatory diseases.
|
| Molecular Formula |
C71H106O32
|
|---|---|
| Molecular Weight |
1471.5822
|
| Exact Mass |
1470.666
|
| CAS # |
1078708-72-1
|
| PubChem CID |
134715185
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.2
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
32
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
103
|
| Complexity |
3000
|
| Defined Atom Stereocenter Count |
34
|
| SMILES |
O([C@H]1[C@@H]([C@H](C[C@@H](CO)O1)O)O)[C@H]1[C@H](C[C@@]2(C)[C@]([H])([C@@]1(C(=O)O)C)CC[C@@]1(C)[C@]3(CO)CC[C@@]4(C(=O)O[C@H]5[C@@H]([C@H]([C@H]([C@@H](C)O5)OC(/C=C/C5C=C(C(=C(C=5)OC)OC)OC)=O)O[C@H]5[C@@H]([C@@H]([C@H]([C@H](C)O5)O)O)O)O[C@H]5[C@@H]([C@@H]([C@H]([C@H](C)O5)O[C@H]5[C@@H]([C@H]([C@@H](CO5)O)O)O)O)O)CC([H])C(C)(C)C[C@@]4([H])C3=CC[C@@]12[H])O.O[H]
|
| InChi Key |
BZKDCAIDWFPAGZ-ZZVFPCDUSA-N
|
| InChi Code |
InChI=1S/C71H106O32/c1-29-43(77)46(80)50(84)60(94-29)100-56-54(98-42(76)15-12-32-22-37(90-9)55(92-11)38(23-32)91-10)31(3)96-63(57(56)101-61-52(86)48(82)53(30(2)95-61)99-59-49(83)44(78)36(75)27-93-59)103-65(89)70-19-18-66(4,5)24-34(70)33-13-14-40-67(6)25-35(74)58(102-62-51(85)47(81)45(79)39(26-72)97-62)69(8,64(87)88)41(67)16-17-68(40,7)71(33,28-73)21-20-70/h12-13,15,22-23,29-31,34-36,39-41,43-54,56-63,72-75,77-86H,14,16-21,24-28H2,1-11H3,(H,87,88)/b15-12+/t29-,30-,31+,34-,35-,36+,39+,40+,41+,43-,44-,45+,46+,47-,48-,49+,50+,51+,52+,53-,54-,56-,57+,58-,59-,60-,61-,62-,63-,67+,68+,69-,70-,71-/m0/s1
|
| Chemical Name |
(2S,3R,4S,4aR,6aR,6bR,8aS,12aS,14aR,14bR)-8a-[(2S,3R,4S,5S,6R)-3-[(2S,3R,4S,5R,6S)-3,4-dihydroxy-6-methyl-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-6-methyl-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-5-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxyoxan-2-yl]oxycarbonyl-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~16.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6795 mL | 3.3977 mL | 6.7954 mL | |
| 5 mM | 0.1359 mL | 0.6795 mL | 1.3591 mL | |
| 10 mM | 0.0680 mL | 0.3398 mL | 0.6795 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
